OpenBench
OpenBench is a fee-for-success contract research organization specializing in early small molecule drug discovery. Their AI-enabled structure-based virtual screening platform screens trillions of compounds to deliver potent, novel, and developable hit series tailored to client-defined success criteria. OpenBench offers transparent pricing, rapid delivery of enriched compound libraries, and a collaborative model that minimizes technical friction and protects client IP with exclusivity. Trusted by over a dozen biotech companies, OpenBench focuses on drugging first-in-class targets, including allosteric and non-functional binding sites, with a 90% success rate in commercial projects. Their approach accelerates discovery timelines and reduces upfront costs by only charging for successful hit series, aligning with modern biotech R&D models.
OpenBench
OpenBench is a fee-for-success contract research organization specializing in early small molecule drug discovery. Their AI-enabled structure-based virtual screening platform screens trillions of compounds to deliver potent, novel, and developable hit series tailored to client-defined success criteria. OpenBench offers transparent pricing, rapid delivery of enriched compound libraries, and a collaborative model that minimizes technical friction and protects client IP with exclusivity. Trusted by over a dozen biotech companies, OpenBench focuses on drugging first-in-class targets, including allosteric and non-functional binding sites, with a 90% success rate in commercial projects. Their approach accelerates discovery timelines and reduces upfront costs by only charging for successful hit series, aligning with modern biotech R&D models.